Furthermore, the canonical changes in plasma VEGF and VEGFR-2 that have been observed with vandetanib in NSCLC [17] and with other VEGFR tyrosine kinase inhibitors across different tumor types [7,30] were not seen in the present study. Here, KDR is linked to neoplasm.